About Alveo Technologies
Alveo Technologies is a company based in Alameda (United States) founded in 2014 by Mike Aicher and Lawrence M Blatt. Alveo Technologies has raised $63.61 million across 3 funding rounds from investors including Gates Foundation and Maxim Group. Alveo Technologies offers products and services including Alveo Sense™ Poultry Avian Influenza Test and Alveo Platform. Alveo Technologies operates in a competitive market with competitors including NeuMoDx, GenMark Diagnostics, Biomeme, Sense Biodetection and Bioskryb, among others.
- Headquarter Alameda, United States
- Founders Mike Aicher, Lawrence M Blatt
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alveo S.R.O.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$63.61 M (USD)
in 3 rounds
-
Latest Funding Round
$16 M (USD), Series A
Mar 29, 2021
-
Investors
Gates Foundation
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alveo Technologies
Alveo Technologies offers a comprehensive portfolio of products and services, including Alveo Sense™ Poultry Avian Influenza Test and Alveo Platform.
Rapid molecular tool for detecting avian influenza in poultry samples.
Handheld analyzer for on-site pathogen testing in various sectors.
People of Alveo Technologies
Unlock access to complete
Unlock access to complete
Funding Insights of Alveo Technologies
Alveo Technologies has successfully raised a total of $63.61M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $16 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $16.0M
-
First Round
First Round
(05 Jan 2018)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series A - Alveo Technologies | Valuation |
investors |
|
| Nov, 2020 | Amount | Grant - Alveo Technologies | Valuation |
investors |
|
| Jan, 2018 | Amount | Series A - Alveo Technologies | Valuation |
investors |
Investors in Alveo Technologies
Alveo Technologies has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Gates Foundation and Maxim Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Financial advisory services are provided across multiple sectors.
|
Founded Year | Domain | Location | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alveo Technologies
Financial Statements - Alveo Technologies
Alveo Technologies Comparisons
Competitors of Alveo Technologies
Alveo Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NeuMoDx, GenMark Diagnostics, Biomeme, Sense Biodetection and Bioskryb, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of a platform for low cost molecular testing
|
|
| domain | founded_year | HQ Location |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| domain | founded_year | HQ Location |
Smartphone-based DNA detection platform is developed for diagnostics.
|
|
| domain | founded_year | HQ Location |
Provider of point of care molecular diagnostics solutions
|
|
| domain | founded_year | HQ Location |
Genome amplification systems for DNA sequencing are developed.
|
Latest news on Alveo Technologies
Frequently Asked Questions about Alveo Technologies
Alveo Technologies was founded in 2014 and raised its 1st funding round 4 years after it was founded.
Alveo Technologies is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
Alveo Technologies is a funded company, having raised a total of $63.61M across 3 funding rounds to date. The company's 1st funding round was a Series A of $47.61M, raised on Jan 05, 2018.
Alveo Technologies is an early-stage biotech company developing point of care molecular diagnostic devices. Alveos technology incorporates cloud-based analytics with rapid, point of care molecular testing to create an integrated, connected solution for infectious disease diagnostics.
Alveo Technologies's top competitors include GenMark Diagnostics, NeuMoDx and Bioskryb.
Alveo Technologies offers Alveo Sense™ Poultry Avian Influenza Test and Alveo Platform.
Alveo Technologies has 2 investors. Key investors include Gates Foundation, and Maxim Group.